Conni Bergmann Koury

Contributing Writer

  • All
  • Deals
  • Devices and Diagnostics
  • Digital
  • Genetics
  • Pharma
With Positive Phase III Results, Oyster Point Pharma Banks $120 Million from Public Offering

July 1 2020

With Positive Phase III Results, Oyster Point Pharma Banks $120 Million from Public Offering

Oyster Point Pharma has taken two big steps recently to advance development of its OC-01 nasal-spray candidate to treat dry eye disease: the closing of ...
Read More
Has Promising Cannabinoid-Based Drug Development Finally Come to Ophthalmology?

June 3 2020

Has Promising Cannabinoid-Based Drug Development Finally Come to Ophthalmology?

Before Tetra Bio-Pharma's recent announcement of US Food and Drug Administration Orphan Drug Designation for its ophthalmic clinical program, ophthalmology was one of the few ...
Read More